AU746647B2 - Guanylhydrazones useful for treating diseases associated with T cell activation - Google Patents

Guanylhydrazones useful for treating diseases associated with T cell activation Download PDF

Info

Publication number
AU746647B2
AU746647B2 AU54360/98A AU5436098A AU746647B2 AU 746647 B2 AU746647 B2 AU 746647B2 AU 54360/98 A AU54360/98 A AU 54360/98A AU 5436098 A AU5436098 A AU 5436098A AU 746647 B2 AU746647 B2 AU 746647B2
Authority
AU
Australia
Prior art keywords
mapk
hiv
pathway
infection
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU54360/98A
Other languages
English (en)
Other versions
AU5436098A (en
Inventor
Michael Bukrinsky
Pamela Cohen
Helena Schmidtmayerova
Kevin Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Picower Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Picower Institute for Medical Research filed Critical Picower Institute for Medical Research
Publication of AU5436098A publication Critical patent/AU5436098A/en
Application granted granted Critical
Publication of AU746647B2 publication Critical patent/AU746647B2/en
Priority to AU2002300386A priority Critical patent/AU2002300386B2/en
Assigned to CYTOKINE PHARMASCIENCES, INC. reassignment CYTOKINE PHARMASCIENCES, INC. Alteration of Name(s) in Register under S187 Assignors: PICOWER INSTITUTE FOR MEDICAL RESEARCH, THE
Assigned to FERRING B.V. reassignment FERRING B.V. Alteration of Name(s) in Register under S187 Assignors: CYTOKINE PHARMASCIENCES, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU54360/98A 1996-11-15 1997-11-14 Guanylhydrazones useful for treating diseases associated with T cell activation Expired AU746647B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002300386A AU2002300386B2 (en) 1996-11-15 2002-08-02 Guanylhydrazones useful for treating diseases associated with T cell activation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3106196P 1996-11-15 1996-11-15
US60/031061 1996-11-15
PCT/US1997/020670 WO1998020868A1 (en) 1996-11-15 1997-11-14 Guanylhydrazones useful for treating diseases associated with t cell activation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2002300386A Division AU2002300386B2 (en) 1996-11-15 2002-08-02 Guanylhydrazones useful for treating diseases associated with T cell activation

Publications (2)

Publication Number Publication Date
AU5436098A AU5436098A (en) 1998-06-03
AU746647B2 true AU746647B2 (en) 2002-05-02

Family

ID=21857458

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54360/98A Expired AU746647B2 (en) 1996-11-15 1997-11-14 Guanylhydrazones useful for treating diseases associated with T cell activation

Country Status (9)

Country Link
US (3) US6143728A (ja)
EP (1) EP0963197B1 (ja)
JP (1) JP2001503775A (ja)
AT (1) ATE454141T1 (ja)
AU (1) AU746647B2 (ja)
CA (1) CA2271693C (ja)
DE (1) DE69739734D1 (ja)
ES (1) ES2339306T3 (ja)
WO (1) WO1998020868A1 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020868A1 (en) * 1996-11-15 1998-05-22 The Picower Institute For Medical Research Guanylhydrazones useful for treating diseases associated with t cell activation
WO2000040235A2 (en) * 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2001240578A1 (en) * 2000-02-02 2001-08-14 Axxima Pharmaceuticals Ag Pharmaceutically active aromatic guanylhydrazones
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU2001269092A1 (en) * 2000-06-27 2002-01-08 Axxima Pharmaceuticals Ag Inhibitors of hepatitis b virus infection
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CA2476896A1 (en) * 2002-02-26 2003-09-04 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
EP1389480A1 (en) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
WO2005000405A2 (en) * 2003-06-06 2005-01-06 The Trustees Of The University Of Pennsylvania P38 kinase inhibitor compositions and methods of use
BR122016015715B8 (pt) 2003-07-23 2021-05-25 Bayer Healthcare Llc composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2005092308A2 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Neural tourniquet
US7244765B2 (en) 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
DK1778265T3 (da) 2004-08-17 2013-06-24 Ferring Bv Guanylhydrazoneforbindelser, sammensætninger, fremgangsmåder og anvendelse
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
JP2008525102A (ja) 2004-12-27 2008-07-17 ノース ショア−ロング アイランド ジューウィッシュ リサーチ インスティテュート 電気的な迷走神経刺激による炎症性障害の処置
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
DE102006028371A1 (de) * 2006-06-19 2007-12-20 Rheinische Friedrich-Wilhelms Universität Mittel gegen Malaria
EP2041078A4 (en) * 2006-06-23 2016-06-01 The Feinstein Inst Medical Res INHIBITORS OF AGGREGATION OF Abeta AND SYNUCLEIN
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
AU2009316801C1 (en) 2008-11-18 2015-12-24 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflammatory stimulation
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和***
US9320773B2 (en) 2010-08-18 2016-04-26 UNIVERSITé LAVAL Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (DCIR) activity and signaling events
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
EP3668402B1 (en) 2017-08-14 2024-07-31 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
IL298193B2 (en) 2020-05-21 2024-01-01 Feinstein Institutes For Medical Research Systems and methods for stimulating the vagus nerve

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8901507A (nl) * 1989-06-14 1991-01-02 Tno Vluchtige aardkalimetaal-organische verbindingen en werkwijze voor de bereiding van gelaagde materialen met aardkalimetaaloxiden of -fluoriden uit deze verbindingen.
DD292376A5 (de) * 1989-08-29 1991-08-01 Berlin-Chemie Ag,De Verfahren zur herstellung eines mittels gegen retrovirale erkrankungen
DD299041A5 (de) * 1989-08-29 1992-03-26 Berlin-Chemie Ag,De Verfahren zur herstellung eines mittels gegen retrovirale erkrankungen
DD299038A5 (de) * 1989-08-29 1992-03-26 Berlin-Chemie Ag,De Verfahren zur herstellung eines mittels gegen retrovirale erkrankungen
US4969305A (en) * 1989-08-31 1990-11-13 Philip Morris Incorporated Indicia applying apparatus
CA2099245A1 (en) * 1991-02-08 1992-08-09 Stanley M. Goldin Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay
US5616578A (en) * 1993-08-26 1997-04-01 The Dupont Merck Pharmaceutical Company Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
US6008255A (en) 1994-01-21 1999-12-28 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
US5599984A (en) 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
US5574040A (en) * 1995-01-06 1996-11-12 Picower Institute For Medical Research Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions
US6369068B1 (en) * 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
EP1017980A4 (en) * 1996-03-12 2002-09-18 Smithkline Beecham Corp METHOD FOR IDENTIFYING PHARMACEUTICALLY ACTIVE COMPOUNDS
WO1998020868A1 (en) 1996-11-15 1998-05-22 The Picower Institute For Medical Research Guanylhydrazones useful for treating diseases associated with t cell activation
US6180686B1 (en) * 1998-09-17 2001-01-30 Thomas M. Kurth Cellular plastic material

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.EXP.MED. MARCH 1996 (V183) PP 927-936 *

Also Published As

Publication number Publication date
ATE454141T1 (de) 2010-01-15
AU5436098A (en) 1998-06-03
WO1998020868A1 (en) 1998-05-22
EP0963197B1 (en) 2010-01-06
US20040171695A1 (en) 2004-09-02
JP2001503775A (ja) 2001-03-21
CA2271693C (en) 2009-01-20
CA2271693A1 (en) 1998-05-22
US6143728A (en) 2000-11-07
ES2339306T3 (es) 2010-05-18
DE69739734D1 (de) 2010-02-25
EP0963197A1 (en) 1999-12-15
EP0963197A4 (en) 2003-04-09
US6673777B1 (en) 2004-01-06
US7741372B2 (en) 2010-06-22

Similar Documents

Publication Publication Date Title
AU746647B2 (en) Guanylhydrazones useful for treating diseases associated with T cell activation
US5750493A (en) Method to improve the biological and antiviral activity of protease inhibitors
Baba et al. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.
US10343985B2 (en) Cryopyrin inhibitors for preventing and treating inflammation
KR960013435B1 (ko) 바이러스 억제제 및 dsRNA를 함유하는 바이러스 감염질환 및 HIV 감염질환 치료용 조성물
Hartmann et al. Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs
WO1992016226A1 (en) Il-1 inhibitors
EP0482081B1 (en) Antiviral composition
CZ20022932A3 (cs) Antagonisté IL-8 receptoru
JPH05504940A (ja) ３’―アジド―２’，３’―ジデオキシ―５―メチルシチジン抗ウィルス性組成物
US6562859B1 (en) Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation
US6358963B1 (en) Antiviral nucleoside analogues
AU2002300386B2 (en) Guanylhydrazones useful for treating diseases associated with T cell activation
EP1159005B1 (en) Pharmaceutical combination of antiviral agents
JP2004509852A (ja) ウイルス感染の治療におけるｉｌ−８受容体アンタゴニストの使用
JP2001527519A (ja) Ｉｌ―８レセプターアンタゴニスト
US6960606B2 (en) Adamantyl Thiazole Thioureas
CA1340519C (en) Antiviral nucleosides
Sethi Zidovudine
US20030216334A1 (en) Methods for inhibiting/treating hiv infections and aids related symptoms
AU2001221154A1 (en) Aromatic and heterocyclic thiazolyl thiourea compounds and use
CA2252583A1 (en) Anticonvulsant pyridinyl benzamide derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)